The Pros-IT CNR project aims to monitor a sample of Italian males ≥18 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life.
Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, naïve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient's health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly.
The study will provide information on patients' quality of life and its variations over time in relation to the treatments received for the prostate cancer.
Aging clinical and experimental research. 2017 Feb 24 [Epub]
Marianna Noale, Stefania Maggi, Walter Artibani, Pier Francesco Bassi, Filippo Bertoni, Sergio Bracarda, Giario Natale Conti, Renzo Corvò, Mauro Gacci, Pierpaolo Graziotti, Stefano Maria Magrini, Riccardo Maurizi Enrici, Vincenzo Mirone, Rodolfo Montironi, Giovanni Muto, Stefano Pecoraro, Angelo Porreca, Umberto Ricardi, Andrea Tubaro, Vittorina Zagonel, Filiberto Zattoni, Gaetano Crepaldi, Pros-IT CNR study group
CNR, Aging Branch, Neuroscience Institute, Via Giustiniani 2, 35128, Padova, Italy. ., CNR, Aging Branch, Neuroscience Institute, Via Giustiniani 2, 35128, Padova, Italy., Azienda Ospedaliera Universitaria integrata di Verona, Verona, Italy., Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore di Milano-sede di Roma, Milan, Italy., Prostate Group of AIRO-Italian Association for Radiation Oncology, Brescia, Italy., Ospedale San Donato, Arezzo, Italy., Ospedale Sant'Anna, Como, Italy., IRCCS San Martino-IST, Genova, Italy., Università di Firenze, Florence, Italy., Ospedale S. Giuseppe, Milano, Italy., Università di Brescia, Brescia, Italy., Università di Roma Sapienza, Roma, Italy., Università degli Studi di Napoli Federico II, Napoli, Italy., Università Politecnica delle Marche, Ancona, Italy., Università Campus Bio-medico, Roma, Italy., Malzoni Center, Avellino, Italy., Policlinico di Abano Terme, Padova, Italy., Università di Torino, Turin, Italy., Ospedale Sant'Andrea, Roma, Italy., Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Università di Padova, Padova, Italy.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/28236267